怡达股份：2025年前三季度净利润约-8983万元

Group 1 - The core viewpoint of the article highlights the financial performance of Yida Co., which reported a revenue of approximately 1.11 billion yuan for the first three quarters of 2025, representing a year-on-year decrease of 16.56% [1] - The net profit attributable to shareholders of the listed company showed a loss of approximately 89.83 million yuan [1] - The basic earnings per share reported a loss of 0.5449 yuan [1] Group 2 - The article also discusses the broader context of the Chinese innovative pharmaceutical market, noting that overseas licensing has generated sales of 80 billion US dollars this year [1] - It features an interview with Lu Gang, a partner at Chuangdong Investment, who comments on the hot secondary market for biomedicine while indicating that fundraising in the primary market is facing challenges [1]